|CATEGORY||Salut, Covid-19, Vacunes|
|DATE:||April 05 2021|
The Chinese Biopharmaceutical company Sinovac Biotech has built CoronaVac, an inactivated-virus vaccine using a non-infectious variant of the virus causing the disease, unable to infect but capable of triggering an immune response.
The results of phase III of the clinical trial, presented on the 5th of February, started on 21 July 2020 in Brazil, Turquey, Indonesia, and Chile, grouping 25.000 participants. The results indicated a 91,25% efficacy.
CoronaVac consists of 2-dose series that are administered with 14 days difference. Almost twenty countries mainly distributed between Latin America and Asia are immunising their population with this vaccine.
The most common side effect, according to the researchers, is pain at the injection site.
CoronaVac vaccine can be stored at a temperature between 2ºC and 8ºC for three years.